burlington-massachusetts
(2)
PAQ Therapeutics
PAQ Therapeutics is a clinical-stage biotechnology company in Burlington, Massachusetts developing a new class of small-molecule degraders that harness autophagy, the body's natural cellular recycling system, to destroy disease-causing proteins. Its proprietary ATTEC (autophagosome-tethering compound) platform aims to eliminate targets that traditional inhibitors cannot reach. The company's lead programs are KRAS degraders - PT0253, a selective KRAS G12D degrader, and PT0511, a pan-KRAS degrader - both in Phase 1 clinical trials for lung, colorectal and pancreatic cancers driven by KRAS mutations.
b Inc.
b Inc. (formerly Vecna) is a Burlington, Massachusetts technology company founded in 1998 by MIT engineers Deborah and Daniel Theobald. It builds automation and telepresence technology that keeps human connection at the center of healthcare, education, government, and tourism - from patient self-service kiosks and intake software used across U.S. hospitals to VGo telepresence robots that let people be present from anywhere. Its guiding belief: technology should serve humanity, not overshadow it.